Endogenous opioid systems alterations in pain and opioid use disorder.
Endogenous opioid systems alterations in pain and opioid use disorder.
复制标题
内源性阿片类药物系统改变疼痛和阿片类药物使用障碍。
DOI:
10.3389/fnsys.2022.1014768
复制
发表时间:
2022
影响因子:
3
通讯作者:
Moron, Jose A.
中科院分区:
文献类型:
--
作者:
Higginbotham, Jessica A.;Markovic, Tamara;Massaly, Nicolas;Moron, Jose A.
关键词:
Decades of research advances have established a central role for endogenous opioid systems in regulating reward processing, mood, motivation, learning and memory, gastrointestinal function, and pain relief. Endogenous opioid systems are present ubiquitously throughout the central and peripheral nervous system. They are composed of four families, namely the μ (MOPR), κ (KOPR), δ (DOPR), and nociceptin/orphanin FQ (NOPR) opioid receptors systems. These receptors signal through the action of their endogenous opioid peptides β-endorphins, dynorphins, enkephalins, and nociceptins, respectfully, to maintain homeostasis under normal physiological states. Due to their prominent role in pain regulation, exogenous opioids—primarily targeting the MOPR, have been historically used in medicine as analgesics, but their ability to produce euphoric effects also present high risks for abuse. The ability of pain and opioid use to perturb endogenous opioid system function, particularly within the central nervous system, may increase the likelihood of developing opioid use disorder (OUD). Today, the opioid crisis represents a major social, economic, and public health concern. In this review, we summarize the current state of the literature on the function, expression, pharmacology, and regulation of endogenous opioid systems in pain. Additionally, we discuss the adaptations in the endogenous opioid systems upon use of exogenous opioids which contribute to the development of OUD. Finally, we describe the intricate relationship between pain, endogenous opioid systems, and the proclivity for opioid misuse, as well as potential advances in generating safer and more efficient pain therapies.
登录
查看更多内容
影响因子:
16.2
作者:
Baliki, Marwan N.;Geha, Paul Y.;Fields, Howard L.;Apkarian, A. Vania
通讯作者:
Apkarian, A. Vania
DOI:
10.1007/s13311-020-00887-6
发表时间:
2020-07
期刊:
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
影响因子:
--
作者:
Bannister K;Dickenson AH
通讯作者:
Dickenson AH
影响因子:
3.3
作者:
Berthele, A;Platzer, S;Tölle, TR
通讯作者:
Tölle, TR
影响因子:
4.2
作者:
Crist, R. C.;Ambrose-Lanci, L. M.;Vaswani, M.;Clarke, T. K.;Zeng, A.;Yuan, C.;Ferraro, T. N.;Hakonarson, H.;Kampman, K. M.;Dackis, C. A.;Pettinati, H. M.;O'Brien, C. P.;Oslin, D. W.;Doyle, G. A.;Lohoff, F. W.;Berrettini, W. H.
通讯作者:
Berrettini, W. H.
DOI:
10.1111/ejn.12829
发表时间:
2015-04
期刊:
The European journal of neuroscience
影响因子:
--
作者:
Beaudry H;Gendron L;Morón JA
通讯作者:
Morón JA